DHEA supplementation confers no additional benefit to that of growth hormone on pregnancy and live birth rates in IVF patients categorized as poor prognosis
MetadataShow full item record
Methods: Data were retrospectively analyzed from 626 women undergoing 626 IVF cycles, where they received no adjuvant, GH alone, or GH-DHEA in combination. A small group received DHEA alone. The utilization of adjuvants was decided between the attending clinician and the patient depending on various factors including cost. Results: Despite patients being significantly older with lower ovarian reserve, live birth rates were significantly greater with GH alone (18.6%) and with GH-DHEA (13.0%) in comparison to those with no adjuvant (p < 0.003). No significant difference was observed between the GH groups (p = 0.181). Overall, patient age, quality of the transferred embryo, and GH treatment were the only significant independent predictors of live birth chance. Following adjustment for patient age, antral follicle count, and quality of transferred embryo, GH alone and GH-DHEA led to a 7.1-fold and 5.6-fold increase in live birth chance, respectively (p < 0.000). Conclusion: These data indicated that GH adjuvant may support more live births, particularly in younger women, and importantly, the positive effects of GH treatment were still observed even if DHEA was also used in combination. However, supplementation with DHEA did not indicate any potentiating benefit or modify the effects of GH treatment. Due to the retrospective design, and the risk of a selection bias, caution is advised in the interpretation of the data.
Showing items related by title, author, creator and subject.
Novel dehydroepiandrosterone troche supplementation improves the serum androgen profile of women undergoing in vitro fertilizationKeane, Kevin; Hinchliffe, P.; Namdar, N.; Conceicao, J.; Newsholme, Philip; Yovich, John (2015)Dehydroepiandrosterone (DHEA) is the most abundant steroid hormone in the circulation and has potent multifunctional activity. Epidemiological evidence suggests that levels of serum DHEA decrease with advancing age, and ...
Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosisKeane, Kevin; Yovich, John; Hamidi, Anahita; Hinchliffe, P.; Dhaliwal, Satvinder S. (2017)Background Patients undergoing in vitro fertilisation (IVF) receive various adjuvant therapies in order to enhance success rates, but the true benefit is actively debated. Growth hormone (GH) supplementation was assessed ...
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 studyAu, H.; Eiermann, W.; Robert, N.; Pienkowski, T.; Crown, J.; Martin, M.; Pawlicki, M.; Chan, Arlene; Mackey, J.; Glaspy, J.; Pintér, T.; Liu, M.; Fornander, T.; Sehdev, S.; Ferrero, J.; Bée, V.; Santana, M.; Miller, D.; Lalla, D.; Slamon, D. (2013)Background. This study aims to describe and compare health- related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast can-cer receiving adjuvant docetaxel and ...